Statement: delusions, ctcae is a disorder characterized by false personal beliefs held contrary to reality, despite contradictory evidence and common sense. the primary trial reports the changes in the number of lesions for patients in its cohorts.
Primary_evidence: Outcome Measurement:    Change in Tumor Size (CTS) From Baseline to the End of Cycle 2   The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment.   Time frame: Baseline up to end of Cycle 2 (Day 42) Results 1:    Arm/Group Title: LY2523355 + Pegfilgrastim or Filgrastim   Arm/Group Description: LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter squared per day [mg/m^2/day]).   Pegfilgrastim or filgrastim administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. Dosage is determined by standard of care.   If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.   Overall Number of Participants Analyzed: 17   Mean (Standard Deviation)   Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.0         (0.08) Results 2:    Arm/Group Title: Ixabepilone   Arm/Group Description: Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles.   Dosage determined by calculating participant's body surface area (40 mg/m^2).   If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.   Overall Number of Participants Analyzed: 11   Mean (Standard Deviation)   Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.1         (0.37)